Prognostic Value of E2F Transcription Factor Expression in Pancreatic Adenocarcinoma

Lin Luo* Gerui Zhang* Taihua Wu Guangzhen Wu

* Lin Luo and Gerui Zhang are the co-first authors

Corresponding Authors: Taihua Wu, e-mail: wutaihuadoc@126.com, Guangzhen Wu, e-mail: wuguang0613@hotmail.com

Financial support: None declared

Conflict of interest: None declared

Background: Pancreatic adenocarcinoma (PAAD) is one of the deadliest types of cancer. In the early stages, patients often have atypical symptoms, making diagnosis difficult. The prognosis of diagnosed patients is very poor and treating PAAD is challenging. Therefore, determining reliable risk factors related to PAAD development is critical for improving patient prognosis. E2F family transcription factors (TFs) are essential regulators of DNA synthesis and cell cycle progression in eukaryotic cells, and they have been identified as prognostic biomarkers associated with multiple cancer types. However, further research is necessary to establish the prognostic relevance of these TFs in PAAD patients.

Material/Methods: We assessed PAAD patient transcriptional and outcome data using the TIMER, ONCOMINE, STRING, GEPIA, cBioPortal, Kaplan-Meier Plotter, GSCALite, and starBase databases.

Results: PAAD tumor tissues exhibited increased expression of E2F1/3/5/7/8 relative to that in normal tissues, while the expression of E2F2/3/6/8 was associated with a more advanced tumor stage. Survival analyses indicated that PAAD patients expressing higher levels of E2F1/2/3/7/8 exhibited shorter overall survival (OS) and disease-free survival (DFS) than patients expressing lower levels of these TFs. In addition, E2F4 and E2F6 overexpression was associated with poorer DFS and OS, respectively. We also found that the expression of E2Fs was significantly correlated with immune infiltrates, including CD8+ T cells, CD4+ T cells, B cells, dendritic cells, neutrophils, and macrophages.

Conclusions: Our study may provide new insights into the optimal choice of immunotherapy and promising novel targets for therapeutic intervention in PAAD patients.

Keywords: E2F Transcription Factors • Pancreatic Adenoma • Prognosis

Full-text PDF: https://www.medscimonit.com/abstract/index/idArt/933443
Background

Pancreatic adenocarcinoma (PAAD) is among the deadliest forms of cancer, with a 5-year survival rate that is under 10% [1]. PAAD incidence has risen in recent years, and because patients with early-stage disease do not exhibit reliable symptoms, it is rarely diagnosed until it is advanced, at which point patient prognosis is very poor. Identifying prognostic biomarkers associated with PAAD patient outcomes is thus vital to better guide patient management efforts and to aid in the formulation of novel therapeutics. E2F family transcription factors (TFs) serve as critical regulators of eukaryotic cell proliferation. Mammals express 8 different E2F family proteins (E2F1-8) that are broadly classified as transcriptional activators (E2F1-E2F3a) or transcriptional repressors (E2F3b-E2F8) [2] and control biological activities such as cell cycle progression, DNA damage responses, cell death, and differentiation in a context-specific manner [3]. E2F TF expression patterns have been shown to be dysregulated in many cancers, including ovarian cancer [4], breast cancer [5], bladder cancer [6], prostate cancer [7], lung adenocarcinoma [8], and PAAD [9].

In an effort to elucidate novel prognostic biomarkers related to PAAD patient outcomes, we employed a series of bioinformatics tools and databases to systematically assess E2F expression patterns in PAAD patients. Through this approach, we explored the relationships between these TFs and patient survival while additionally clarifying their potential regulatory roles in cells to guide future studies of PAAD patient treatment.

Material and Methods

Ethics Statement

The Academic Committee of Dalian Medical University approved this study in accordance with the Declaration of Helsinki. As all the datasets were derived from previously published literature, informed consent for research use was previously provided.

ONCOMINE Analysis

The ONCOMINE (https://www.oncomine.org/resource/main.html) database compiles gene chip data pertaining to a large collection of tumor types, enabling data mining related to tumor-related transcription profiles [10]. The mRNA levels of E2F family members in clinical tumor samples in the ONCOMINE database were compared to the levels in normal control samples using t-tests, with significance thresholds of P<0.01 and fold-change (FC) >2.

TIMER Analysis

The online TIMER tool (http://timer.cistrome.org/) enables systematic analyses of immune cell populations associated with 23 cancers compiled in The Cancer Genome Atlas (TCGA) [11]. Herein, the TIMER tool was utilized to assess E2F family TF expression in a range of tumor types. The relationship between the transcription level of E2Fs and the level of immune cell infiltration in PAAD was evaluated.

GEPIA Analysis

The GEPIA webserver (http://gepia.cancer-pku.cn/) enables the standardized analysis of RNA-seq data pertaining to 9736 tumors and 8587 normal samples derived from the TCGA and GTex databases, allowing users to compare differential gene expression and patient survival outcomes, calculate correlations between gene expression patterns, conduct dimensionality reduction analyses, and to assess other gene-related information of interest [12]. Herein, GEPIA was utilized to assess the differential expression E2F family TFs in tumors and normal samples, with P<0.05 and |log2FC| >1 as the threshold for statistical significance.

Kaplan-Meier Plotter Analysis

The Kaplan-Meier Plotter database (www.kmplot.com) compiles cancer-related gene expression and survival outcome data [13,14]. Herein, this database was used to examine the association between E2F family protein expression in PAAD patients and the overall survival (OS) and disease-free survival (DFS) of these patients as assessed using Kaplan-Meier curves following patient stratification into high- and low-expression groups for each gene of interest based upon median E2F expression levels in a given patient cohort. This tool provided P values, median mRNA expression levels, hazard ratios (HRs), and 95% confidence intervals (CIs) corresponding to these analyses.

TCGA Data and cBioPortal

The TCGA is a compilation of pathological and sequencing-related data associated with 30 cancer types [15]. The Provisional TCGA PAAD dataset incorporates data from 186 cases, and this database was selected for analyses of E2F expression using cBioPortal (http://www.cbioportal.org/) [16,17]. Each gene was analyzed for factors such as mutational profiles, copy number variations (CNVs) from GISTIC, mRNA expression Z-scores (RNA-Seq V2 RSEM), and protein expression Z-scores (RPPA). In addition, coexpression and network analyses were performed based on the instructions provided by cBioPortal.
E2F1 expression level (log2 RSEM)

ACC.Tumor
BLCA.Tumor
BLCA.Normal
BRCA.Tumor
BRCA.Normal
BRCA-Basal.Tumor
BRCA-Her2.Tumor
BRCA-Luminal.Tumor
CESC.Tumor
CHOL.Tumor
CHOL.Normal
COAD.Tumor
COAD.Normal
DLBC.Tumor
ESCA.Tumor
ESCA.Normal
GBM.Tumor
HNSC.Tumor
HNSC.Normal
HNSC-HPVpos.Tumor
HNSC-HPVneg.Tumor
KICH.Tumor
KICH.Normal
KIRC.Tumor
KIRC.Normal
KIRP.Tumor
KIRP.Normal
LAML.Tumor
LGG.Tumor
LIHC.Tumor
LIHC.Normal
LUAD.Tumor
LUAD.Normal
LUSC.Tumor
LUSC.Normal
MESO.Tumor
OV.Tumor
PAAD.Tumor
PCPG.Tumor
PRAD.Tumor
PRAD.Normal
READ.Tumor
READ.Normal
SARC.Tumor
SKCM.Tumor
SKCM.Metastasis
STAD.Tumor
STAD.Normal
TGCT.Tumor
THCA.Tumor
THCA.Normal
THYM.Tumor
UCEC.Tumor
UCEC.Normal
UCS.Tumor
UVM.Tumor

E2F2 expression level (log2 RSEM)

ACC.Tumor
BLCA.Tumor
BLCA.Normal
BRCA.Tumor
BRCA.Normal
BRCA-Basal.Tumor
BRCA-Her2.Tumor
BRCA-Luminal.Tumor
CESC.Tumor
CHOL.Tumor
CHOL.Normal
COAD.Tumor
COAD.Normal
DLBC.Tumor
ESCA.Tumor
ESCA.Normal
GBM.Tumor
HNSC.Tumor
HNSC.Normal
HNSC-HPVpos.Tumor
HNSC-HPVneg.Tumor
KICH.Tumor
KICH.Normal
KIRC.Tumor
KIRC.Normal
KIRP.Tumor
KIRP.Normal
LAML.Tumor
LGG.Tumor
LIHC.Tumor
LIHC.Normal
LUAD.Tumor
LUAD.Normal
LUSC.Tumor
LUSC.Normal
MESO.Tumor
OV.Tumor
PAAD.Tumor
PCPG.Tumor
PRAD.Tumor
PRAD.Normal
READ.Tumor
READ.Normal
SARC.Tumor
SKCM.Tumor
SKCM.Metastasis
STAD.Tumor
STAD.Normal
TGCT.Tumor
THCA.Tumor
THCA.Normal
THYM.Tumor
UCEC.Tumor
UCEC.Normal
UCS.Tumor
UVM.Tumor

E2F3 expression level (log2 RSEM)

ACC.Tumor
BLCA.Tumor
BLCA.Normal
BRCA.Tumor
BRCA.Normal
BRCA-Basal.Tumor
BRCA-Her2.Tumor
BRCA-Luminal.Tumor
CESC.Tumor
CHOL.Tumor
CHOL.Normal
COAD.Tumor
COAD.Normal
DLBC.Tumor
ESCA.Tumor
ESCA.Normal
GBM.Tumor
HNSC.Tumor
HNSC.Normal
HNSC-HPVpos.Tumor
HNSC-HPVneg.Tumor
KICH.Tumor
KICH.Normal
KIRC.Tumor
KIRC.Normal
KIRP.Tumor
KIRP.Normal
LAML.Tumor
LGG.Tumor
LIHC.Tumor
LIHC.Normal
LUAD.Tumor
LUAD.Normal
LUSC.Tumor
LUSC.Normal
MESO.Tumor
OV.Tumor
PAAD.Tumor
PCPG.Tumor
PRAD.Tumor
PRAD.Normal
READ.Tumor
READ.Normal
SARC.Tumor
SKCM.Tumor
SKCM.Metastasis
STAD.Tumor
STAD.Normal
TGCT.Tumor
THCA.Tumor
THCA.Normal
THYM.Tumor
UCEC.Tumor
UCEC.Normal
UCS.Tumor
UVM.Tumor

Indexed in: [Current Contents/Clinical Medicine] [SCI Expanded] [ISI Alerting System] [ISI Journals Master List] [Index Medicus/MEDLINE] [EMBASE/Excerpta Medica] [Chemical Abstracts/CAS]

Luo L. et al:
Prognostic value of E2F transcription factor expression
© Med Sci Monit, 2021; 27: e933443

This work is licensed under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
**Figure G**

E2F expression level (log2 RSEM)

**Figure H**

E2F expression level (log2 RSEM)
### Figure 1

Expression levels of the E2F family of proteins in different cancers. (A-H) E2F family TF expression levels in different cancer types and corresponding normal tissues as assessed with the TIMER database. (I) The transcriptional expression of E2F family members in different cancers and corresponding normal tissues as assessed with the ONCOMINE database.
Transcripts per Million (TPM)

A

B

C

D

PAAD

Expression-log2 (TPM+1)

Indexed in: [Current Contents/Clinical Medicine] [SCI Expanded] [ISI Alerting System] [ISI Journals Master List] [Index Medicus/MEDLINE] [EMBASE/Excerpta Medica] [Chemical Abstracts/CAS]

This work is licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
Figure 2. GEPIA-based assessment of E2F protein expression levels in PAAD. (A) Differential E2F protein expression in PAAD and normal tissue samples was assessed using the GEPIA database. (B-I) Box plots were used to demonstrate differences in E2F expression between PAAD and normal tissues in the GEPIA database.
Luo L. et al: Prognostic value of E2F transcription factor expression
© Med Sci Monit, 2021; 27: e933443

DATABASE ANALYSIS

Indexed in: [Current Contents/Clinical Medicine] [SCI Expanded] [ISI Alerting System] [ISI Journals Master List] [Index Medicus/MEDLINE] [EMBASE/Excerpta Medica] [Chemical Abstracts/CAS]

This work is licensed under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
Protein–Protein Interaction (PPI) Network and Path Analyses

The STRING database (v 10.5; https://string-db.org/) was employed to generate a PPI network for E2F family proteins [18], with 30 putative E2F-interacting proteins additionally being identified. The FUNRICH website was used to assess the potential functions of the genes included in the above PPI networks, with the Cytoscape ClueGo plug-in being used to conduct GO and KEGG enrichment analyses of these genes. P<0.05 served as the significance threshold for these analyses.

GSCALite Analysis

The interactive GSCALite tool (http://bioinfo.life.hust.edu.cn/web/GSCALite/) enables users to conduct genomic analyses of particular cancers and to visualize correlations, gene expression data, and related information in a flexible manner [19]; available reporting information included differential gene expression, OS, CNVs, single-nucleotide variations, normal tissue expression levels, miRNA regulation, methylation, and drug sensitivity data. Herein, this tool was utilized to examine relationships between E2F family members and cancer-related pathways and to assess how these relationships were associated with tumor sensitivity to a range of anticancer drugs. PAAD patient OS and DFS were also analyzed with the OncoLnc website (http://www.oncolnc.org/).

StarBase Analysis

The starBase database (http://starbase.sysu.edu.cn/agoClipRNA.php?source=incRNA&flag) [20] was employed to assess miRNA/IncRNA regulatory relationships in PAAD, with the results of these analyses then used to construct ceRNA networks and to perform coexpression analyses. Differentially expressed IncRNAs and mRNAs associated with PAAD were submitted to starBase, and Kaplan-Meier analyses with log-rank tests were used to assess the prognostic relationship between these IncRNAs, associated mRNAs, and PAAD patient OS, with P<0.05 and |log2FC| >0.5 as the significance criteria.

Human Protein Atlas (HPA)

Images of immunohistochemistry (IHC) staining for PAAD and normal tissues were collected from the HPA (https://www.proteinatlas.org/), which applies transcriptomics and proteomics to provide different atlases based on tissue type, cell type, and pathology.

Results

Assessment of E2F Family Gene Expression in PAAD Patients

To explore the differential expression of the 8 known E2F family TFs in PAAD patients, we used the TIMER database to compare relative expression levels of E2F1-8 in normal tissues and PAAD tumors using the TCGA dataset (Figure 1A-1H). This analysis revealed that all 8 of these E2F family members were upregulated in certain tumors, with E2F3 being significantly upregulated in pancreatic cancer patients in 6 datasets, E2F7 and E2F8 significantly upregulated in pancreatic cancer patients in 4 and 5 datasets, respectively, and E2F1 and E2F5 upregulated in pancreatic cancer patients (Figure 1I). IHC of E2F expression in PAAD was studied using the HPA (Supplementary Figure 1).

The protein levels of E2F1 (Supplementary Figure 1A) were increased in PAAD tissues compared with paracancerous tissues (Supplementary Figure 1B).

Figure 3. (A-H) Correlation between the expression of E2F family proteins and PAAD tumor stage as assessed using GEPIA.
E2F1

HR=2.06 (1.37-3.11)
logrank P=0.00042

Number at risk
Low 117 43 13 6 1
High 60 80

Expression
Low
High

E2F2

HR=2.4 (1.27-3.87)
logrank P=0.0045

Number at risk
Low 44 17 7 4 1
High 133 41 10 4 0

Expression
Low
High

E2F3

HR=1.81 (1.16-2.85)
logrank P=0.0087

Number at risk
Low 69 108 29 7 1
High 69 96 29 2 0

Expression
Low
High

E2F4

HR=0.72 (0.47-1.08)
logrank P=0.011

Number at risk
Low 81 96 27 11 2
High 43 134 7 51 2

Expression
Low
High

E2F5

HR=0.75 (0.47-1.22)
logrank P=0.25

Number at risk
Low 120 32 6 0 0
High 57 26 11 0 1

Expression
Low
High

E2F6

HR=0.49 (0.3-0.8)
logrank P=0.0036

Number at risk
Low 70 28 7 3 0
High 48 115 7 2 0

Expression
Low
High

E2F7

HR=2.54 (1.59-4.07)
logrank P=0.00042

Number at risk
Low 70 28 7 3 0
High 48 115 7 2 0

Expression
Low
High

E2F8

HR=2.09 (1.35-3.24)
logrank P=0.00073

Number at risk
Low 129 48 11 8 0
High 48 115 7 2 0

Expression
Low
High

A
**Figure 4. (A, B)** Evaluation of the prognostic relevance of E2F family TF mRNA expression levels in PAAD patients, as assessed using the Kaplan-Meier Plotter tool.
**DATABASE ANALYSIS**

Prognostic value of E2F transcription factor expression

© Med Sci Monit, 2021; 27: e933443

Luo L. et al:

Indexed in: [Current Contents/Clinical Medicine] [SCI Expanded] [ISI Alerting System] [ISI Journals Master List] [Index Medicus/MEDLINE] [EMBASE/Excerpta Medica] [Chemical Abstracts/CAS]

This work is licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)

---

**A**

![Diagram of E2F transcription factors]

**B**

Genetic alterations

- Missense Mutation (unknown significance)
- Truncating Mutation (unknown significance)
- Amplification
- Deep deletion
- mRNA high
- mRNA low
- No alterations

Pancreatic adenocarcinoma
Figure 5. Functional analysis of E2F family members. (A) A PPI network of E2F family TFs expressed in PAAD was constructed with the STRING tool. (B) An analysis of E2F family protein expression and mutations in PAAD patients was conducted using cBioPortal. (C) The GEPIA database was used to conduct an E2F family member coexpression analysis in PAAD. (D) An E2F pathway analysis was performed using cBioPortal.
Associations Between E2F Gene Expression and the Clinicopathological Characteristics of PAAD Patients

Next, we explored the differences in E2F expression levels in PAAD and normal tissues using the GEPIA dataset, revealing that all 8 E2F family members (E2F1-8) were expressed at significantly higher levels in PAAD tissues relative to normal pancreatic tissues (Figure 2). We additionally examined the association between these E2F family members and tumor stage, revealing that E2F2/3/6/8 expression levels were significantly associated with tumor stage, whereas E2F1/4/5/7 expression levels were not (Figure 3).

Upregulation of E2F1/2/3/7/8 and Downregulation of E2F4/5 are Associated with Better PAAD Patient Prognosis

We then examined the association between E2F expression levels and PAAD patient survival using the Kaplan-Meier Plotter tool and corresponding log-rank tests, which indicated that higher levels of E2F1/2/3/7/8 and lower levels of E2F6 expression were significantly associated with OS (P<0.05) (Figure 4A), while increased E2F1/2/3/7/8 mRNA levels and decreased E2F4 mRNA levels were significantly related to DFS (P<0.05) (Figure 4B). Specifically, higher E2F1/2/3/7/8 levels were associated with poorer OS and DFS, whereas lower E2F4 and E2F6 levels were associated with poorer DFS and poorer OS, respectively.

Predicted Functional Roles of E2F Family TFs and Related Genes in PAAD Patients

We next constructed PPI networks using the STRING tool to evaluate potential interacting proteins with E2F family members (Figure 5A). In addition, alterations in E2F proteins were assessed with the cBioPortal tool by analyzing 186 PAAD samples (TCGA, Provisional; Figure 5B) [16]. The GEPIA tool was then used to conduct analyses of E2F family TFs following Pearson’s correlation. The following significant positive correlations were identified through this analysis: E2F1 with E2F2, E2F7, and E2F8; E2F2 with E2F1 and E2F8; E2F3 with E2F4 and E2F6; E2F4 with E2F3, E2F6, and E2F8; E2F5 with E2F6; E2F6 with E2F3, E2F4, and E2F5; E2F7 with E2F1; and E2F8 with E2F1, E2F2, and E2F4 (Figure 5C). A pathway analysis of these E2F family members was then conducted with the cBioPortal tool (Figure 5D).

We then expanded these analyses by constructing PPI networks incorporating 30 E2F-related proteins (Figure 6A, Table 1).
B) Biological process for E2Fs related genes

- Regulation of nucleobase, nucleoside, nucleotide, and nucleic acid metabolism: 61.6% (p < 0.001)
- Regulation of cell cycle: 22.2% (p < 0.001)
- DNA replication: 8.3% (p < 0.001)

C) Cellular component for E2Fs related genes

- Nucleoplasm: 69.4% (p < 0.001)
- Chromosome: 22.2% (p < 0.001)
- Nucleus: 8.3% (p < 0.001)
- Origin recognition complex: 8.3% (p < 0.001)
- Cyclin-dependent protein kinase holoenzyme complex: 8.3% (p < 0.001)

D) Molecular function for E2Fs related genes

- DNA binding: 69.4% (p < 0.001)
- Kinase activity: 22.2% (p < 0.001)
- Transcription factor activity: 8.3% (p < 0.001)
Luo L. et al:
Prognostic value of E2F transcription factor expression
© Med Sci Monit, 2021; 27: e933443

DATABASE ANALYSIS

E

DNA replication

Human T-cell leukemia virus 1 infection

Cell cycle

TGF-beta signaling pathway

Cellular senescence

DATABASE ANALYSIS

This work is licensed under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)

Indexed in: [Current Contents/Clinical Medicine] [SCI Expanded] [ISI Alerting System] [ISI Journals Master List] [Index Medicus/MEDLINE] [EMBASE/Excerpta Medica] [Chemical Abstracts/CAS]
Figure 6. Functional analyses of E2F-related proteins in PAAD. (A) E2Fs and the top 30 E2F-related interacting proteins were incorporated into a PPI network generated using the STRING tool. (B-D) GO enrichment analyses for these 38 E2F family members and related proteins were conducted with the FUNRICH tool. (E) KEGG pathway enrichment analyses for these 38 E2F family members and related proteins were conducted using the ClueGo plug-in in Cytoscape software. (F) KEGG pathways regulated by E2F family members.

Table 1. The top 30 E2F-related proteins identified using the STRING tool.

| E2Fs related genes | Genes name |
|--------------------|------------|
| E2Fs family genes (n=8) | E2F1, E2F2, E2F3, E2F4, E2F5, E2F6, E2F7, E2F8 |
| Non-E2Fs family genes (n=30) | MCM3, CDT1, CCNA2, TFDP1, L3MBTL2, RNF2, ORC2, CDK1, BUB1B, BM1, ORC1, MCM5, RBL1, CDK4, ENSG00000269905, ORC5, CDKN1B, CDC20, CDK2, CBX7, CDC6, MCM7, DP2, MCM4, CDKN1A, MCM6, RB1, MCM2, RBL2, MAD2L1 |
Luo L. et al: Prognostic value of E2F transcription factor expression © Med Sci Monit, 2021; 27: e933443

Indexed in: [Current Contents/Clinical Medicine] [SCI Expanded] [ISI Alerting System] [ISI Journals Master List] [Index Medicus/MEDLINE] [EMBASE/Excerpta Medica] [Chemical Abstracts/CAS]
Figure 7. Mutations and functions of E2F family members as analyzed using GSCALite. (A) CNV analysis of E2F family members. (B) Correlations between the methylation of E2F family members and their expression in PAAD. (C) E2F family member-related pathway activity in PAAD. (D) The role of E2F family members in the context of drug sensitivity.
Luo L. et al: Prognostic value of E2F transcription factor expression © Med Sci Monit, 2021; 27: e933443

DATABASE ANALYSIS

This work is licensed under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
DATABASE ANALYSIS

Luo L. et al:
Prognostic value of E2F transcription factor expression
© Med Sci Monit, 2021; 27: e933443

Indexed in: [Current Contents/Clinical Medicine] [SCI Expanded] [ISI Alerting System] [ISI Journals Master List] [Index Medicus/MEDLINE] [EMBASE/Excerpta Medica] [Chemical Abstracts/CAS]

This work is licensed under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
Figure 8. Prognostic analyses of E2F gene-related miRNAs. (A) Survival outcomes associated with miRNAs predicted to regulate E2F family members were assessed with the GSCALite tool. (B, F) Survival outcomes associated with E2F1-related miRNAs were assessed with Oncolnc. (C-E, G) Survival outcomes associated with E2F7-related miRNAs were assessed with Oncolnc.
DATABASE ANALYSIS

A

NEAT1
AC005082.1
AL035681.1
NNT-AS1
AC107083.2
AL513534.1
LINC00240
AP000974.1
AC003297.2

ARHGAP21P1-BPTF1-DENTP1-AS1
LIGAP1-AS1
AP003476.1
GAS5
AL122035.1
AP006248.3
EBLN3P
LINC01703

AC005332.6
PSMD6-AS2
AC008666.1
SNHG6
MBC-AS1
OIP5-AS1
AC084117.1
AC127502.2
HCG11

AC105339.2
AL358472.3
AC106744.1
AC073857.1
AC106827.3
LINC01111
LINC00332.7

AC087868.1
AL162171.3
LINC00865
LINC-PINT
AC026356.2
LMP25-AS1
LINC00265
AC00120.1
LMR181A1HG

AC16026.1
LINC00174
AC022144.1
AC144548.1
AL137127.1
LIGAP1-AS1
SNHG14
AC016717.2
TUG1

RNR3P2
AC090957.1
ZN5F1-AS1
GABPB1-AS1
SNHG5
TENDEA-DFP1-178F10.1
WASP2
AL291056.1

AC087388.1
AL392172.1
MIATNB
AC122023.1
TRG-AS1
AC005261.1
AC013652.1
LINC00937
AC016676.2

KCNQ1OT1
AC239869.1
DUXAP8
AC022322.1
AC023355.1
THLMP2-AS4
LINC00647
AC078846.1
AC35256.3

NORAD
AL513318.2
LINC00907
SHBPS-AS1
AC157526.1
DLX6-AS1
AC005538.2
AC068864.1
MALAT1

RPARP-AS1
AL139407.1

B

LINC01278
LINC00661
PECBP1-AS1
AC116913.1
AC002116.1
AL162586.1
AC124319.4
LINC01164
AP001157.1
TBC1D9-AS1

DANCR
AC092611.3
HAP23-2.72
LINC01654
AC024506.3
AC007996.1
RPI-1-176F10.3
AC003848.4
PICG1R
AC091676.5

PARD6G-AS1
BX294692.2
AC120024.12
AL049840.4
BDNF-AS
XIST
AC026362.1
AC105026.2
LINC01939
LMR282BCCH

AC007760.1
AC040975.1
AL136375.1
DUBR
AC08M082.1
ZFHX2-AS1
LINC00943
AC005154.1
LINC00281

AC009135.2
AC239328.1
PLAC4
AC0VR28-AS1
AC046156.1
AC101034.5
LAL.S8-AS1
ST28-AS1
AL069718.2
MPP-T11

AC005746.1
AL117209.1
AL117503.2
INE1
AL132780.1
AC022097.1
AC007228.2
AC100442.1
TAP1-AS1
AC091271.1

AC009943.3
AC009962.3
AC005322.1
GLOR
LINC00270
LINC00687
LINCQ1OT1
MR194-2HG2
AC022167.2
AL162586.1

PAK5-AS1
AC104514.1
GUSBP11
AC021097.1
AL177312.2
MR6435-2HG
LINCRESS1
AL617172.1
AC245014.7
KLF7-T11

AL138820.1
AC007336.3
LINC01128
PCAT18
AC027990.3
CAPYB1-AS1
AL068875.2
AC108134.2
AC018862.1
S47924.1

AC002535.1
AC16447.1
AC020917.4
AC009237.1
FNK2-AS1
DATA2-AS1
RPARP-AS1
AC009078.3
NEAT1
FAM27C

AC10336.1
NOP14-AS1
AC004656.1
AL00635.1
CMNN-MIN-AS1
AC02348.3
AC091152.4
AC005332.6
CYTOR
AC003900.1
Luo L et al: Prognostic value of E2F transcription factor expression
© Med Sci Monit, 2021; 27: e933443

DATABASE ANALYSIS

DATABASE ANALYSIS

This work is licensed under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
Disease free survival

- Logrank p=0.023
- HR(high)=1.7
- p(HR)=0.025
- n(high)=89
- n(low)=89

Overall survival

- Logrank p=0.12
- HR(high)=1.4
- p(HR)=0.12
- n(high)=89
- n(low)=89

PAAD
(num(T)=179; num(N)=171)

Expression -log2(TPM+1)

Months

Percent survival

Pertcent survival

Logrank p=0.023
HR(high)=1.7
p(HR)=0.025
n(high)=89
n(low)=89

Low HCG11 group
High HCG11 group

Low HCG11 group
High HCG11 group
Prognostic value of E2F transcription factor expression

Luo L. et al.
© Med Sci Monit, 2021; 27: e933443

DATABASE ANALYSIS

Indexed in: [Current Contents/Clinical Medicine] [SCI Expanded] [ISI Alerting System] [ISI Journals Master List] [Index Medicus/MEDLINE] [EMBASE/Excerpta Medica] [Chemical Abstracts/CAS]

Protein Array Data (PAAD) (num(T)=179; num(N)=171)

Expression -log2(TPM+1)

Disease free survival
Low MIR4435-2HG group
High MIR4435-2HG group
Logrank p=0.0044
HR(high)=1.9
p(HR)=0.0051
n(high)=89
n(low)=89

Overall survival
Low MIR4435-2HG group
High MIR4435-2HG group
Logrank p=0.0032
HR(high)=1.9
p(HR)=0.0037
n(high)=89
n(low)=89

F

Indexed in: [Current Contents/Clinical Medicine] [SCI Expanded] [ISI Alerting System] [ISI Journals Master List] [Index Medicus/MEDLINE] [EMBASE/Excerpta Medica] [Chemical Abstracts/CAS]

Luo L. et al:
Prognostic value of E2F transcription factor expression
© Med Sci Monit, 2021; 27: e933443

DATABASE ANALYSIS

Indexed in: [Current Contents/Clinical Medicine] [SCI Expanded] [ISI Alerting System] [ISI Journals Master List] [Index Medicus/MEDLINE] [EMBASE/Excerpta Medica] [Chemical Abstracts/CAS]

F

Indexed in: [Current Contents/Clinical Medicine] [SCI Expanded] [ISI Alerting System] [ISI Journals Master List] [Index Medicus/MEDLINE] [EMBASE/Excerpta Medica] [Chemical Abstracts/CAS]

Luo L. et al:
Prognostic value of E2F transcription factor expression
© Med Sci Monit, 2021; 27: e933443

DATABASE ANALYSIS

Indexed in: [Current Contents/Clinical Medicine] [SCI Expanded] [ISI Alerting System] [ISI Journals Master List] [Index Medicus/MEDLINE] [EMBASE/Excerpta Medica] [Chemical Abstracts/CAS]

Luo L. et al:
Prognostic value of E2F transcription factor expression
© Med Sci Monit, 2021; 27: e933443

DATABASE ANALYSIS

Indexed in: [Current Contents/Clinical Medicine] [SCI Expanded] [ISI Alerting System] [ISI Journals Master List] [Index Medicus/MEDLINE] [EMBASE/Excerpta Medica] [Chemical Abstracts/CAS]

Luo L. et al:
Prognostic value of E2F transcription factor expression
© Med Sci Monit, 2021; 27: e933443

DATABASE ANALYSIS

Indexed in: [Current Contents/Clinical Medicine] [SCI Expanded] [ISI Alerting System] [ISI Journals Master List] [Index Medicus/MEDLINE] [EMBASE/Excerpta Medica] [Chemical Abstracts/CAS]

Luo L. et al:
Prognostic value of E2F transcription factor expression
© Med Sci Monit, 2021; 27: e933443

DATABASE ANALYSIS

Indexed in: [Current Contents/Clinical Medicine] [SCI Expanded] [ISI Alerting System] [ISI Journals Master List] [Index Medicus/MEDLINE] [EMBASE/Excerpta Medica] [Chemical Abstracts/CAS]

Luo L. et al:
Prognostic value of E2F transcription factor expression
© Med Sci Monit, 2021; 27: e933443

DATABASE ANALYSIS

Indexed in: [Current Contents/Clinical Medicine] [SCI Expanded] [ISI Alerting System] [ISI Journals Master List] [Index Medicus/MEDLINE] [EMBASE/Excerpta Medica] [Chemical Abstracts/CAS]

Luo L. et al:
Prognostic value of E2F transcription factor expression
© Med Sci Monit, 2021; 27: e933443

DATABASE ANALYSIS

Indexed in: [Current Contents/Clinical Medicine] [SCI Expanded] [ISI Alerting System] [ISI Journals Master List] [Index Medicus/MEDLINE] [EMBASE/Excerpta Medica] [Chemical Abstracts/CAS]

Luo L. et al:
Prognostic value of E2F transcription factor expression
© Med Sci Monit, 2021; 27: e933443

DATABASE ANALYSIS

Indexed in: [Current Contents/Clinical Medicine] [SCI Expanded] [ISI Alerting System] [ISI Journals Master List] [Index Medicus/MEDLINE] [EMBASE/Excerpta Medica] [Chemical Abstracts/CAS]

Luo L. et al:
Prognostic value of E2F transcription factor expression
© Med Sci Monit, 2021; 27: e933443

DATABASE ANALYSIS

Indexed in: [Current Contents/Clinical Medicine] [SCI Expanded] [ISI Alerting System] [ISI Journals Master List] [Index Medicus/MEDLINE] [EMBASE/Excerpta Medica] [Chemical Abstracts/CAS]

Luo L. et al:
Prognostic value of E2F transcription factor expression
© Med Sci Monit, 2021; 27: e933443

DATABASE ANALYSIS

Indexed in: [Current Contents/Clinical Medicine] [SCI Expanded] [ISI Alerting System] [ISI Journals Master List] [Index Medicus/MEDLINE] [EMBASE/Excerpta Medica] [Chemical Abstracts/CAS]

Luo L. et al:
Prognostic value of E2F transcription factor expression
© Med Sci Monit, 2021; 27: e933443

DATABASE ANALYSIS

Indexed in: [Current Contents/Clinical Medicine] [SCI Expanded] [ISI Alerting System] [ISI Journals Master List] [Index Medicus/MEDLINE] [EMBASE/Excerpta Medica] [Chemical Abstracts/CAS]

Luo L. et al:
Prognostic value of E2F transcription factor expression
© Med Sci Monit, 2021; 27: e933443

DATABASE ANALYSIS

Indexed in: [Current Contents/Clinical Medicine] [SCI Expanded] [ISI Alerting System] [ISI Journals Master List] [Index Medicus/MEDLINE] [EMBASE/Excerpta Medica] [Chemical Abstracts/CAS]
Disease free survival

- Logrank p = 0.039
- HR(high) = 1.6
- p(HR) = 0.042
- n(high) = 88
- n(low) = 87

Overall survival

- Logrank p = 0.6
- HR(high) = 1.1
- p(HR) = 0.6
- n(high) = 88
- n(low) = 87
Figure 9. Associations between ceRNA networks and PAAD patient outcomes. (A-D) The Cytoscape tool was used to predict lncRNAs upstream of specific miRNAs of interest. (E-G) The prognostic relevance of putative upstream lncRNAs was assessed. (H) Putative ceRNA (lncRNA/miRNA/mRNA) regulatory relationships identified in the present analysis.
**Figure 10.** Coexpression analyses of associations between E2F family members and related noncoding RNAs. (A) Coexpression relationship analysis of E2F1/miRNA26a-5p/HCG11 was conducted using the starBase tool. (B) A coexpression relationship analysis of E2F7 and related noncoding RNAs was conducted using the starBase tool.
DATABASE ANALYSIS

genomic abnormalities have value in the context of screening
regulation, and DNA damage responses. Specific E2F proteins
of cancer-associated pathways, the results of which revealed
alyzed E2F family TFs in PAAD (Figure 7C). These findings suggested that specific E2F-related
 genomic abnormalities have value in the context of screening

Assessment of the Mechanistic Roles of E2F Family
Members and Associated ceRNA Network Construction

To explore the mechanisms and prognostic relevance of E2F family members in PAAD patients, we leveraged the GSCALite tool to assess E2F CNVs and found that E2F1/5 amplification and E2F2/3 deletion were significantly associated with PAAD patient status was negatively correlated with the expression of the an
gene expression (E2F2/3 deletion were significantly associated with PAAD patient
to assess E2F CNVs and found that E2F1/5 amplification and
ily members in PAAD patients, we leveraged the GSCALite tool
members in particular biological processes (BPs),
cellular components (CCs), and molecular functions (MFs)
(Figure 6B-6D). Enriched BPs included regulation of nucleo-
base, nucleoside, nucleotide, and nucleic acid metabolism and
regulation of cell cycle; enriched CCs included the nucleoplasm,
chromosome, nucleus, origin recognition complex, and cyclin-
dependent protein kinase holoenzyme complex; and enriched
MFs included DNA binding. Enriched KEGG pathways associat-
ed with these 38 E2F family members and related genes were
 Additionally identified (Figure 6E), revealing that they are as-
associated with the cell cycle signaling pathway (Figure 6F).

GO enrichment analyses of the 38 genes included in the
above PPI network were then conducted using the FUNRICH
tool (https://david.ncifcrf.gov/), which assessed the enrich-
ment of these genes in particular biological processes (BPs),
cellular components (CCs), and molecular functions (MFs)
(Figure 7A). We then explored the
importance of E2F family members in a range of cancer-associated pathways, the results of which revealed that they are involved in cyclin activation, apoptotic pathway regulation, and DNA damage responses. Specific E2F proteins were able to inhibit the hormone AR and RAS/MAPK pathways
(Figure 7C). These findings suggested that specific E2F-related
 genomic abnormalities have value in the context of screening

for therapeutic efficacy and clinical responses to certain medica-
tions. In the drug sensitivity analyses, E2F2/3/8 expression lev-
els were negatively correlated with drug resistance (Figure 7D).

Next, we sought to establish an miRNA-related regulatory
network corresponding to PAAD by identifying upstream miR-
NAs associated with PAAD patient survival using GSCALite
(Figure 8A), with further evaluation of the prognostic value with
the Oncomlnc website (http://www.oncomlnc.org/). This approach identified 4 relevant miRNAs, including E2F1-related miR-126-
3p, and overexpression of miR-126-3p was linked to a better patient prognosis (P<0.05) (Figure 8B). The other 3 miRNAs,
miR-26a-5p, miR-140-3p, and miR-125a-5p, were associated
with the expression of E2F7, with its overexpression linked to
better patient outcomes (P<0.05) (Figure 8C-8E). Using star-
Base, we predicted upstream IncRNA regulators of these miR-
NAs (Figure 9A-9D). The GEPIA database indicated that the In-
cRNAs HCG11, MIR4435-2HG, and LINC00313 were all expressed
at high levels and were closely linked to PAAD patient OS and
tolerance level of MIR4435-2HG and LINC00313 but negatively correlated with
expression of HCG11 expression in PAAD patients (Figure 10A),
and E2F7 expression was positively correlated with the levels
of mir-10-3p and mir-26a-5p (Figure 10B).

The Transcription Level of E2Fs and Various Levels of
Immune Infiltration in PAAD

To elucidate the relationship between E2Fs and the inflamma-
tory response and immune cell infiltration, we used the TIMER

Figure 7A

Figure 7B

Figure 7C

Figure 7D

Figure 7E

Figure 7F

Figure 7G

Figure 7H

Figure 11. The relationship between E2F expression levels and immune cell infiltration in PAAD (TIMER). The correlation between the abundance of immune cells and the expression of E2F1 (A), E2F2 (B), E2F3 (C), E2F4 (D), E2F5 (E), E2F6 (F), E2F7 (G), and E2F8 (H) in PAAD.
database (http://timer.cistrome.org/) for analysis; the results of which are shown in Figure 11A and indicate that the level of E2F expression is associated with the level of immune infiltration in PAAD. We found that E2F2 expression was positively correlated with the infiltration of B cells, neutrophils, and dendritic cells (Figure 11B). E2F3/4/5/6 expression was positively correlated with the infiltration of B cells, CD8+ T cells, macrophages, neutrophils, and dendritic cells (Figure 11C-11F), and E2F7 expression was positively correlated with the infiltration of CD8+ T cells and dendritic cells (Figure 11G). E2F8 expression was positively correlated with the infiltration of B cells and dendritic cells but was negatively correlated with the infiltration of CD4+ T cells (Figure 11H).

Discussion

The dysregulation of E2F family TFs has been reported in many tumor types [4-9], and the advent of novel high-throughput transcriptomic technologies has emphasized the importance of studying the functional roles of these TFs as regulators of PAAD oncogenic progression through mechanisms associated with a range of noncoding RNAs. Indeed, lncRNA/miRNA/mRNA signaling and the related regulatory mechanisms have been extensively documented in multiple cancer types [21], and the roles of these RNAs in PAAD must be clarified to better establish key diagnostic and prognostic biomarkers related to this cancer type. Herein, we conducted novel analyses of the expression and molecular roles of E2F family TFs in PAAD and explored their associations with patient outcomes by analyzing lncRNA/miRNA/mRNA signaling axes via a series of bioinformatics approaches.

E2F1 was the first identified E2F family member, and it can control the G1/S-phase transition by regulating DNA replication and controlling its own expression in a feedback loop [22]. We observed significant E2F1 overexpression in PAAD cells, which is known to promote oncogenesis and tumor cell proliferation [23]. While ONCOMINE and TCGA analyses indicated that PAAD tissues expressed higher levels of E2F1 than the healthy tissues did, this TF was not associated with clinical characteristics in PAAD patients. Despite this, higher E2F1 expression was associated with poorer patient OS and DFS. Constructed ceRNA networks further identified miR-126-3p to be related to E2F1 expression and poor patient prognosis, with HCG11 identified as an upstream lncRNA predicted to regulate miR-126-3p expression and to be negatively correlated with E2F1 expression.

E2F2 is also a key regulator of PAAD onset and progression, with miR-214-5p having previously been identified as an oncogenic regulator of this TF in PAAD [24]. Herein, we did not detect any significant difference in E2F2 expression between PAAD and normal tissues, but we did observe a significant relationship between the expression of this TF and PAAD tumor stage. Higher levels of E2F2 expression were associated with worse PAAD patient OS and DFS, and GSCAlite analyses suggested that E2F2 expression levels are positively correlated with drug resistance.

E2F3 was previously identified as a key regulator of aggressive behaviors in prostate cancer and was reported to be related to tumor stage, grade, and proliferation in bladder cancer [25]. Sun et al [26] determined that the lncRNA NEAT1 can drive the progression of NSCLC by functioning as a miR-377-3p ceRNA to promote E2F3 upregulation. Consistent with these prior reports, we detected high levels of E2F3 expression in PAAD tissues relative to control tissue samples, with this expression being correlated with tumor stage. High E2F3 expression was also associated with worse PAAD patient OS and DFS and was positively correlated with drug resistance.

The E2F4 transcriptional repressor can suppress the proliferation of lung cancer cells [27]. We did not detect any significant change in E2F4 expression when comparing PAAD and normal tissue samples, and the expression of this TF was unrelated to PAAD patient tumor stage. However, high E2F4 levels were correlated with better DFS in PAAD patients but were unrelated to OS. These results are in line with the ability of E2F4 to function as a tumor suppressor.

E2F5 has been shown to be expressed at high levels in glioblastoma and prostate cancer [28,29]. While we observed increased E2F5 expression in PAAD tissues compared to normal tissues, it was unrelated to PAAD patient tumor stage or survival outcomes.

E2F6 is known to function as an oncogene in lung cancer, and miR-424 can suppress its expression and consequently disrupt A549 cell proliferation and migration [29,30]. We observed no significant difference in E2F6 expression in PAAD, although it was related to patient tumor staging. Additionally, no association between E2F6 expression and patient prognosis was detected.

E2F7 is a tumor suppressor gene encoded on chromosome 12q21.2 that controls cell cycle progression [31]. We observed significantly increased E2F7 expression in PAAD patient tumors relative to control tissues, and higher expression of this TF was associated with worse PAAD patient OS and DFS. However, the expression of E2F7 was unrelated to other clinical characteristics of PAAD patients. Three total miRNAs were identified as having a relationship with E2F7 (miR-140-3p, miR-26a-5p, and miR-125a-5p), and their overexpression was related to poor patient outcomes. Using the starBase tool, we additionally identified MIR4435-2HG and LINCO00313 as putative upstream lncRNAs that were positively correlated with E2F7 expression in...
PAAD, and the expression of this TF was negatively correlated with the expression of miR-26a-5p and miR-140-3p.

E2F8 can block the activity of other E2F family TFs and bind in a dominant-negative fashion to the cyclin D1 promoter [32], but it has not been studied in the context of PAAD. We found that PAAD tumors exhibited increased E2F8 expression relative to that in normal tissues and that the expression of this TF was related to tumor stage. In addition, higher E2F8 expression was linked to poorer OS and DFS in PAAD patients, and E2F8 levels were positively correlated with drug resistance.

Conclusions

In summary, we observed marked upregulation of E2F1-8 in PAAD, suggesting that these TFs play key roles in the onset and progression of this deadly form of malignancy. Specifically, we determined that E2F1/2/3/7/8 may represent viable prognostic biomarkers of PAAD patient survival, whereas E2F2/3/6/8 levels were significantly related to tumor stages in these patients. As such, E2F2/3/8 may represent promising targets for PAAD treatment, although additional research will be essential to confirm the validity of these results and the utility of E2Fs as therapeutic targets or prognostic biomarkers. The expression of E2Fs and the infiltration of the 6 immune cell types in PAAD suggests that E2Fs may be involved in the regulation of PAAD tumor immunity. This indicates that E2Fs not only can be used as a prognostic indicator of patients with PAAD but also reflect the patients’ immune status.

Declaration of Figure Authenticity

All figures submitted have been created by the authors, who confirm that the images are original with no duplication and have not been previously published in whole or in part.

Supplementary Data

Supplementary Figure 1. The protein levels (https://www.proteinatlas.org/) of E2F1 (A) were increased in PAAD tissues compared with paracancerous tissues (B).
References:

1. Rawla P, Sunkara T, Gaduputi V. Epidemiology of pancreatic cancer: Global trends, etiology and risk factors. World J Oncol. 2019;10(1):10-27
2. Chen HZ, Tsai SY, Leone G. Emerging roles of E2Fs in cancer: An exit from cell cycle control. Nat Rev Cancer. 2009;9:785-97
3. Attwooll C, Denchi EL, Helin K. The E2F family: specific functions and overlapping interests. EMBO J. 2004;23(24):4709-16
4. Reimer D, Sadr S, Wiedemair A, et al. Expression of the E2F family of transcription factors and its clinical relevance in ovarian cancer. Ann NY Acad Sci. 2010;1191(1):270-3
5. Sun C, Li S, Hu W, et al. Comprehensive analysis of the expression and prognosis for E2Fs in human breast cancer. Mol Ther J Am Soc Gene Ther. 2019;27(6):1153-65
6. Santos M, Dueñas M, Garcíaescudero R, et al. In vivo disruption of an Rb-E2F2/FHI signaling loop causes bladder cancer. Cancer Res. 2014;74(22):6565-77
7. Kaseb AO, Kurnyka C, Welsh EA, et al. Early2 factor (E2F) deregulation is a prognostic and predictive biomarker in lung adenocarcinoma. Oncotarget. 2016;7(50):22254-65
8. Sun F, Lin Y, Li S, Gao J, et al. MiR-210 knockdown promotes the development of pancreatic cancer via upregulating E2F3 expression. Eur Rev Med Pharmacol. 2018;22(24):8640-48
9. Rhodes DR, Kalyana Sundaram S, Mahavisno V, et al. Oncomine3.0: Genes, pathway, and networks in a collection of 18,000 cancer gene expression profiles. Neoplasia (New York NY). 2007;9(2):166-80
10. Li T, Fan J, Wang B, et al. TIMER: A web server for comprehensive analysis of tumor-infiltrating immune cells. Cancer Res. 2017;77(22):e108-10
11. Tang Z, Li C, Kang B, et al. GEPRA: A web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017;45(W1):198-102
12. Gyorffy B, Surwinski P, Budczies J, Lanczyk A. Online survival analysis software to assess the prognostic value of biomarkers using transcriptionic data in non-small-cell lung cancer. PloS One. 2013;8(12):e82241
13. Nagy A, Lanczyk A, Menyhart G, Gyorffy B. Validation of miRNA prognostic power in hepatocellular carcinoma using expression data of independent datasets. Sci Rep UK. 2018;8(1):9227
14. Tomczak K, Czerwinska P, Wiznerowicz M. Review The Cancer Genome Atlas (TCGA): An immeasurable source of knowledge. Contemp Oncol (Pozn). 2015;19(A2):A68-77
15. Attwooll C, Denchi EL, Helin K. The E2F family: specific functions and overlapping interests. EMBO J. 2004;23(24):4709-16
16. Reimer D, Sadr S, Wiedemair A, et al. Expression of the E2F family of transcription factors and its clinical relevance in ovarian cancer. Ann NY Acad Sci. 2010;1191(1):270-3
17. Cerami E, Gao J, Dogrusoz U, et al. The cBio cancer genomics portal: An open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2(5):404-1
18. Szklarczyk D, Gable AL, Lyon D, et al. STRING v11: Protein–protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 2019;47(D1):D607-13
19. Liu CJ, Hu FT, Xia MX et al. GSCAI: A web server for gene set cancer analysis. Bioinformatics. 2018;34(21):3771-72
20. Li JH, Liu S, Zhou H, et al. starBasev2.0: Decoding miRNA-ceRNA, miRNA-nrRNA and protein-RNA interaction networks from large-scale CLIP-Seq data. Nucleic Acids Res. (2014;42(Database issue)):D92-97
21. Ye S, Yang L, Zhao X, et al. Bioinformatics method to predict two regulation mechanism: TF miRNA-miRNA and lncRNA-miRNA-miRNA in pancreatic cancer. Cell Biochem Biophys. 2019;70(3):1849-58
22. Jiang H, Martin V, Alonso M, et al. RB-E2F1: molecular rheostat for autophagy and apoptosis. Autophagy. 2010;6(8):1216-17
23. Ma L, Tian X, Wang F, et al. The long noncoding RNA H19 promotes cell proliferation via E2F-1 in pancreatic ductal adenocarcinoma. Cancer Biol Ther. 2016;17(10):1051-61
24. Yao Z, Chen Q, Ni Z, et al. Long non-coding RNA Differentiation Antagonizing Nonproteincoding RNA (DANCR) promotes proliferation and invasion of pancreatic cancer by sponging miR-214-5p to regulate E2F2 expression. Med Sci Monit. 2019;25:4544-52
25. Olsson AV, Feber A, Edwards S, et al. Role of E2F expression in modulating cellular proliferation rate in human bladder and prostate cancer cells. Oncogene. 2007;26(7):1028-37
26. Sun C, Li S, Zhang F, et al. Long noncoding RNA NEAT1 promotes non-small cell lung cancer progression through regulation of miR-377-3p to regulate E2F3 pathway. Oncotarget. 2016;7:51784-814
27. Brown KC, Witte TR, Hardman WE, et al. Capsacin displays anti-proliferative activity against human small cell lung cancer in cell culture and nude mice models via the E2F pathway. PloS One. 2010;5:e10243
28. Fang DZ, Wang YP, Liu J, et al. MicroRNA-129-3p suppresses tumor growth by targeting E2FS in glioblastoma. Eur Rev Med Pharmacol Sci. 2018;22:1044-50
29. Li SL, Sui Y, Sun J, et al. Identification of tumor suppressive role of microRNA-132 and its www.aging-us.com 987 AGING target gene in tumorigene sis of prostate cancer. Int J Mol Med. 2018;41:2429-33
30. Sun CC, Zhou Q, Hu W, et al. Transcriptional E2F2/3/5 as potential targets and transcriptional E2F3/6/7 as new biomarkers for the prognosis of human lung carcinoma. Aging (Albany NY). 2018;10(5):973-87
31. Carvajal LA, Hamard PI, Tonnessen C, Manfredi JJ. E2F7, a novel target, is required for lung adenocarcinoma cell survival and tumor growth. Autophagy. 2010;6(8):1216-17
32. Deng Q, Wang Q, Zong YW, et al. E2F8 contributes to human hepatocellular carcinoma via regulating cell proliferation. Cancer Res. 2010;70:782-91